Andrew Waters, PhD, a basic scientist at the University of Cincinnati Cancer Center and assistant professor within the Division of Surgical Oncology and the Department of Cancer Biology at UC, runs a research lab focusing on the molecular consequences and resistance mechanisms to KRAS inhibitors.

The University of Cincinnati Cancer Center Clinical Trials Office recently opened a trial to study the efficacy of LN-145 on patients with advanced lung cancer. This treatment involves the infusion of patients’ own immune cells, tumor-infiltrating lymphocytes (TIL), to evaluate the efficacy of LN-145 as determined by objective response rates (ORR).

The Greater Cincinnati STEM Collaborative (GCSC) is a nonprofit that prepares students for future careers and educational pathways in science, technology, engineering and mathematics.

The K program (KL2 and CT2) Career Development program is focused on training the next generation of diverse, multidisciplinary clinical and translational scientists.

The Biomedical Research and Mentoring Program (RaMP) offers first-and second-year undergraduate University Honors students with training and experience in high-level biomedical research.